Saturday 17 October 2026
Export ASND’s income statement to Excel — free account
Ascendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024. In the quarter to June 2026, revenue grew 119.9%, EPS grew 612.3%, free cash flow grew 2,335.9% and total debt fell 41.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
225.78
0.84
−0.37%
Follow ASND
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 24.33 | 19.23 |
P/S ratio |
16.72 | 15.86 | 14.15 | 14.16 | |
P/FCF ratio |
0.00 | 251.54 | 287.13 | 44.29 | |
P/Operating CF |
6,759.70 | 154.27 | (1,561.25) | 52.39 | |
P/B ratio |
0.00 | 0.00 | 24.70 | 10.28 | |
Price to Tangible BV |
0.00 | 0.00 | 24.89 | 10.30 | |
EV/Sales |
17.16 | 16.22 | 14.53 | 13.81 | |
EV/EBITDA |
0.00 | 0.00 | 3,004.22 | 52.11 | |
EV/Operating CF |
(109.45) | 216.68 | 216.16 | 41.43 | |
EV/FCF |
(103.62) | 257.17 | 294.85 | 43.20 | |
Quick Ratio |
0.70 | 0.72 | 0.68 | 2.23 | |
Current Ratio |
1.03 | 1.04 | 1.00 | 2.99 | |
Net Debt/EBITDA |
17.98 | 36.90 | 11.15 | (1.61) | |
Debt/Assets |
70.46% | 66.93% | 44.76% | 19.69% | |
Debt/Equity |
(4.67) | (5.35) | 1.84 | 0.31 | |
Asset Turnover |
0.57 | 0.59 | 0.58 | 0.62 | |
Operating CF/Net income |
(0.03) | (1.95) | (0.01) | 1.36 | |
Capex/Depreciation |
(0.05) | (0.73) | (1.83) | (0.70) | |
Interest Coverage |
0.16 | 0.04 | 0.37 | 15.56 | |
Research and Development Expense of Revenue |
31.31% | 33.08% | 23.94% | 22.37% | |
Selling, General and Administrative Expense of Revenue |
53.08% | 56.19% | 58.89% | 51.09% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
15.09% | 10.98% | 12.31% | 8.67% | |
Graham Net Nets |
(0.03) | (0.03) | (0.03) | 0.04 | |
Graham Number |
17.87 | 16.95 | 44.25 | 90.00 | |
Earnings Yield |
(2.13%) | (1.97%) | 4.11% | 5.20% | |
Free Cash Flow Yield |
(0.99%) | 0.40% | 0.35% | 2.26% | |
Revenue per Share |
4.11 | 4.61 | 4.68 | 6.13 | |
Operating CF per Share |
0.03 | 1.38 | (0.15) | 5.09 | |
Capex per Share |
0.00 | (0.06) | (0.15) | (0.06) | |
Free Cash Flow per Share |
0.03 | 1.32 | (0.29) | 5.03 | |
Cash per Share |
10.37 | 11.50 | 10.87 | 14.68 | |
Shareholders Equity per Share |
(3.35) | (3.04) | 9.26 | 25.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.35) | (3.04) | 9.26 | 25.96 | |
Free Cash Flow |
1.56 | 80.13 | (18.06) | 323.87 | |
Working Capital |
36.58 | 44.80 | (5.18) | 1,076.11 | |
Capital Expenditures |
(0.23) | (3.65) | (9.03) | (3.70) | |
Net Current Asset Value |
(363.58) | (403.24) | (459.93) | 628.88 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 55.60 | |
Capex to Sales |
0.00 | 0.01 | 0.03 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 57.00 | |
| Other line items | |||||
Average Receivables |
113.74 | 185.21 | 155.52 | 199.09 | |
Average Payables |
87.32 | 103.44 | 90.43 | 113.61 | |
Average Inventory |
322.45 | 330.52 | 338.33 | 352.75 | |
Average Assets |
1,276.26 | 1,375.03 | 1,731.43 | 1,946.47 | |
Average Common Equity |
(155.24) | (149.30) | 185.58 | 728.64 |
Columns are period end dates